 |
Vol.63 No.1 contents | Japanese/English |
 | Full Text of PDF (416K) Article in Japanese |
- Original Article -
Thyroid Transcription Factor-1, Tumor Proportion Score and Treatment Effect in Combination Therapy with Carboplatin, Pemetrexed, and Pembrolizumab as a First-line Therapy
Fukuko Okabe1, Shingo Sato1, Takafumi Yanase1, Takatoshi Higuchi1, Kiyohide Komuta1, Naoko Morishita1, Kunimitsu Kawahara2,3, Hidekazu Suzuki11Department of Thoracic Oncology, 2Department of Pathology, Osaka Habikino Medical Center, Japan, 3Division of Pathology for Regional Communication, Kobe University Graduate School of Medicine, Japan
Objective. We analyzed the efficacy of carboplatin+pemetrexed+pembrolizumab for advanced non-squamous non-small cell lung cancer by the thyroid transcription factor-1 (TTF-1) and tumor proportion score (TPS) expression. Methods. Twenty-seven patients who started this treatment at our institution from January 2019 to December 2021 were analyzed retrospectively. Results. In the TTF-1-positive group, the progression-free survival (PFS) was significantly prolonged in TPS-positive cases (TPS-negative/TPS-positive: 8.4 months/24.5 months, hazard ratio 0.17 [95% confidence interval {CI}: 0.03-0.92]; p=0.02). The analysis was divided into two groups: both TTF-1- and TPS-positive and others (TTF-1-positive and TPS-negative, TTF-1-negative and TPS-positive and both negative). The median PFS for others/both-positive was 6.4 months/24.5 months (hazard ratio 0.39 [95% CI: 0.12-1.25]; p=0.09), and the PFS tended to be longer in the both-positive group than in the others. Conclusion. This regimen achieves the best response in patients positive for both TTF-1 and TPS, so others should consider using alternative regimens.
key words: Non-small cell lung cancer, Immune checkpoint inhibitor, TTF-1, PD-L1, Pemetrexed
Received: July 27, 2022
Accepted: September 1, 2022
JJLC 63 (1): 15-21, 2023
